The aspartyl (asparaginyl) beta-hydroxylase in carcinomas

Frontiers in Bioscience - Landmark

Volumn 20, Issue 5, 2015, Pages 902-909

  Yang, Hui ^a   Li, Jing ^a   Tang, Ruihua ^a   Li, Ji ^a   Liu, Yaxiong ^a   Ye, Linjie ^a   Shao, Dongyan ^a   Jin, Mingliang ^a   Huang, Qingsheng ^a   Shi, Junling ^a  

^a NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

Author keywords

AAH; Hepatocellular carcinoma; ICAMs; LFA 1; PI3K; Review

Indexed keywords

ASPARTIC ACID 2-OXOGLUTARATE-DEPENDENT DIOXYGENASE; MIXED FUNCTION OXIDASE;

DIGESTIVE SYSTEM TUMOR; ENZYMOLOGY; HUMAN; LIVER TUMOR; LUNG TUMOR; METABOLISM; NERVOUS SYSTEM TUMOR;

DIGESTIVE SYSTEM NEOPLASMS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIXED FUNCTION OXYGENASES; NERVOUS SYSTEM NEOPLASMS;

EID: 84918806120     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4344     Document Type: Review

References (52)

1. Monkovic DD, VanDusen WJ, Petroski CJ, Garsky VM, Sardana MK, Zavodszky P, Stern AM, Friedman PA. Invertebrate aspartyl/asparaginyl beta-hydroxylase: potential modification of endogenous epidermal growth factor-like modules. Biochem Biophys Res Commun 189(1):233-241(1992) DOI: 10.1016/0006-291X(92)91549-6
2. Dinchuk JE, Henderson NL, Burn TC, Huber R, Ho SP, Link J. Aspartyl beta-hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin. J Biol Chem 275(50):39543-39554(2000) DOI: 10.1074/jbc.M006753200
3. Dinchuk JE, Focht RJ, Kelley JA, Henderson NL, Zolotarjova NI, Wynn R. Absence of post-translational aspartyl beta-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J Biol Chem 277(15):12970-12977(2002) DOI: 10.1074/jbc.M110389200
4. Cantarini MC, de la Monte SM, Pang M. Aspartyl-asparagyl β hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and Notch signaling mechanisms. Hepatology 44(2):446-457(2006) DOI: 10.1002/hep.21272
5. Lindsell CE, Shawber CJ, Boulter J, Weinmaster G. Jagged: a mammalian ligand that activates Notch1. Cell 80(6)909-917(1995) Doi not found.
6. de La Coste A, Freitas AA. Notch signaling: distinct ligands induce specific signals during lymphocyte development and maturation. Immunol Lett 102(1):1-9(2006) DOI: 10.1016/j.imlet.2005.06.014
7. Dinchuk JE, Focht RJ, Kelley JA, Henderson NL, Zolotarjova NI, Wynn R. Absence of post-translational aspartyl betahydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J Biol Chem 277(15):12970-12977(2002) DOI: 10.1074/jbc.M110389200
8. Song K, Xue XP, Wang W, Huyan T, Wang H, Yang H, Xie Q. The distribution and expression pro-files of Aspartyl/ Asparaginyl beta-hydroxylase (ASPH) in some tumorous cell lines and tissues. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 26(2):141-4(2010) Doi not found.
9. Xue T, Xue XP, Huang QS, Wei L, Sun K, Xue T. Monoclonal antibodies against human aspartyl (asparaginyl) beta-hydroxylase developed by DNA immunization. Hybridoma (Larchmt) 28(4):251-7(2009) DOI: 10.1089/hyb.2009.0017
10. Yang H, Song K, Xue T, Xue XP, Huyan T, Wang W, Wang H. The distribution and expression profiles of human Aspartyl/ Asparaginyl beta-hydroxylase in tumor cell lines and human tissues. Oncol Rep 24(5):1257-64(2010) Doi not found.
11. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 383(9935): 2168-79(2014) DOI: 10.1016/S0140-6736(13)61903-0
12. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33(6):1353-7(2001) DOI: 10.1053/jhep.2001.25087
13. Maeda T, Taguchi K, Aishima S, Shimada M, Hintz D, Larusso N, Gores G, Tsuneyoshi M, Sugimachi K, Wands JR, de la Monte SM. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev 28(5):313-8(2004) DOI: 10.1016/j.cdp.2004.06.001
14. Maeda T, Sepe P, Lahousse S, Tamaki S, Enjoji M, Wands JR, de la Monte SM. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol 38(5):615-22(2003) DOI: 10.1016/S0168-8278(03)00052-7
15. Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 60(5):1261-6(2000) Doi not found.
16. Noda T, Shimoda M, Ortiz V, Sirica AE, Wands JR. Immunization with aspartate- β-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma. Hepatology 55(1):86-97(2012) DOI: 10.1002/hep.24629
17. Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR, Friedman PA. Overexpression of human aspartyl(asparaginyl)betahydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 98(6):1313-23(1996) DOI: 10.1172/JCI118918
18. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, Greten TF. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 48(5):599-641(2012) DOI: 10.1016/j.ejca.2011.12.021
19. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27(9):1485-1491(2009) DOI: 10.1200/JCO.2008.20.7753
20. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 61(2):69-90(2011) DOI: 10.3322/caac.20107
21. Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 31(11):1409-1420(2010) DOI: 10.1038/aps.2010.142
22. Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181-182:43-47(2002) DOI: 10.1016/S0300-483X(02)00253-6
23. Merle P, Trepo C. Molecular mechanisms underlying hepatocellular carcinoma. Viruses 1(3):852-872(2009) DOI: 10.3390/v1030852
24. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 25(1):16-27(2005) DOI: 10.1111/j.1478-3231.2005.01016.x
25. Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 28(2):160-174 (2008) DOI: 10.1111/j.1478-3231.2007.01637.x
26. Durr R, Caselmann WH. Carcinogenesis of primary liver malignancies. Langenbecks Arch Surg 385(3):154-161 (2000) DOI: 10.1007/s004230050259
27. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27(1):55-76 (2007) DOI: 10.1055/s-2006-960171
28. Jain S, Singhal S, Lee P, Xu R. Molecular genetics of hepatocellular neoplasia. Am J Transl Res 2(1):105-118 (2010) Doi not found.
29. Sia D, Villanueva A. Signaling pathways in hepatocellular carcinoma. Oncology 81(Suppl 1):18-23 (2011) DOI: 10.1159/000333254
30. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29(36):4989-5005(2010) DOI: 10.1038/onc.2010.236
31. Aref AM, Hoa NT, Ge L, Agrawal A, Dacosta-Iyer M, Lambrecht N, Ouyang Y. HCA519/TPX2. a potential T-cell tumor-associated antigen for human hepatocellular carcinoma. Onco Targets Ther 7:1061-70(2014) Doi not found.
32. Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong WM, Xia Y, Zou QF, Xi T, Shen F, Wang HY, Wu MC. Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 52(1):164-73(2010) DOI: 10.1002/hep.23650
33. Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands J. Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol 56(5):1129-35(2012) DOI: 10.1016/j.jhep.2011.12.016
34. de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ. Aspartyl- (asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol 44(5):971-83(2006) DOI: 10.1016/j.jhep.2006.01.038
35. Longato L, de la Monte S, Kuzushita N, Horimoto M, Rogers AB, Slagle BL. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 49(6):1935-43(2009) DOI: 10.1002/hep.22856
36. Aihara A, Huang CK, Olsen MJ, Lin Q, Chung W, Tang Q, Dong X, Wands JR. A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology 60(4):1302-13 (2014) DOI: 10.1002/hep.27275
37. Palumbo KS, Wands JR, Safran H, King T, Carlson RI, de la Monte SM. Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas 25(1):39-44(2002) DOI: 10.1097/00006676-200207000-00010
38. Feldmann G, Nattermann J, Nischalke HD, Gorschlüter M, Kuntzen T, Ahlenstiel G. Detection of human aspartyl (asparaginyl) beta-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer. Endoscopy 38(6):604-9(2006) DOI: 10.1055/s-2006-925065
39. Wang J, de la Monte SM, Sabo E, Kethu S, Tavares R, Branda M, Simao L, Wands JR, Resnick MB. Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol 38(1):17-25(2007) DOI: 10.1016/j.humpath.2006.07.009
40. Dinchuk JE, Henderson NL, Burn TC, Huber R, Ho SP, Link J. Aspartyl beta -hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin. J Biol Chem 275(50):39543-54(2000) DOI: 10.1074/jbc.M006753200
41. Ho SP, Scully MS, Krauthauser CM, Wexler EJ, Stow MD, Dinchuk JE, Kerr JS, Friedman PA. Antisense oligonucleotides selectively regulate aspartyl betahydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivo. J Pharmacol Exp Ther 302(2):795-803(2002) DOI: 10.1124/jpet.302.2.795
42. Finotti A, Treves S, Zorzato F, Gambari R, Feriotto G. Upstream stimulatory factors are involved in the P1 promoter directed transcription of the A beta H-J-J locus. BMC Mol Biol 9:110(2008) DOI: 10.1186/1471-2199-9-110
43. Lee JH. Overexpression of humbug promotes malignant progression in human gastric cancer cells. Oncol Rep 19(3):795-800(2008) Doi not found.
44. Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, Simao L, Wands JR, Resnick MB, Wang L. Prognostic value of aspartyl (asparaginyl)-betahydroxylase/ humbug expression in non-small cell lung carcinoma. Hum Pathol 40(5):639-44(2009) DOI: 10.1016/j.humpath.2008.11.001
45. Ho SP, Scully MS, Krauthauser CM, Wexler EJ, Stow MD, Dinchuk JE, Kerr JS, Friedman PA. Antisense oligonucleotides selectively regulate aspartyl betahydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivo. J Pharmacol Exp Ther 302(2):795-803(2002) DOI: 10.1124/jpet.302.2.795
46. Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR, de la Monte SM. Role of the aspartyl-asparaginyl-betahydroxylase gene in neuroblastoma cell motility. Lab Invest 82(7):881-91(2002) DOI: 10.1097/01.LAB.0000020406.916 89.7F
47. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schänzer A, Meletis K. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133(Pt 4):983-95(2010) DOI: 10.1093/brain/awq042
48. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 7(1):45-61(2005) Doi not found.
49. Carter JJ, Tong M, Silbermann E, Lahousse SA, Ding FF, Longato L, Roper N, Wands JR, de la Monte SM. Ethanol impaired neuronal migration is associated with reduced aspartyl-asparaginyl-beta-hydroxylase expression. Acta Neuropathol 116(3):303-15(2008) DOI: 10.1007/s00401-008-0377-z
50. de la Monte SM, Tong M, Carlson RI, Carter JJ, Longato L, Silbermann E, Wands JR. Ethanol inhibition of aspartyl-asparaginyl- beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration. Alcohol 43(3):225-40(2009) DOI: 10.1016/j.alcohol.2008.09.009
51. Lawton M, Tong M, Gundogan F, Wands JR, de la Monte SM. Aspartyl- (asparaginyl) beta-hydroxylase, hypoxiainducible factor-alpha and Notch crosstalk in regulating neuronal motility. Oxid Med Cell Longev 3(5):347-56(2010) DOI: 10.4161/oxim.3.5.13296
52. Lahousse SA, Carter JJ, Xu XJ, Wands JR, de la Monte SM. Differential growth factor regulation of aspartyl-(asparaginyl)-betahydroxylase family genes in SH-Sy5y human neuroblastoma cells. BMC Cell Biol 7:41(2006) DOI: 10.1186/1471-2121-7-41